Budde, L. E., Sehn, L. H., Matasar, M., Schuster, S. J., Assouline, S., Giri, P., Kuruvilla, J., Canales, M., Dietrich, S., Fay, K., Ku, M., Nastoupil, L., Cheah, C. Y., Wei, M. C., Yin, S., Li, C., Huang, H., Kwan, A., Penuel, E., & Bartlett, N. L. (2022). safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. Lancet oncology, 23(8), 1055–1065. http://access.bl.uk/ark:/81055/vdc_100159752671.0x000020